AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23146973 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102
Study 23146973 — intervention group
Group type: EXPERIMENTAL
Intervention: PTX‐3 levels
Number of subjects: 102
Study 22003345 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaboxadol 10 mg
Number of subjects: 822
Study 22003345 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaboxadol 15 mg
Number of subjects: 822
Study 22003345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 822
Study 19765309 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer‐led plus Screening Access (PL)
Number of subjects: 1554
Study 19765309 — intervention group
Group type: COMPARATOR
Intervention: Screening Access only (SCR)
Number of subjects: 1554
Study 17805214 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 9.4+/‐4.2 mg/day
Number of subjects: 19
Study 15542042 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 58
Study 15542042 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/day
Number of subjects: 58
Study 15542042 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day and 120 mg/day (pooled)
Number of subjects: 58
Study 15542042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 11479482 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 40
Study 11479482 — intervention group
Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 40
Study 11479482 — intervention group
Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 40
Study 10709892 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive nursing care
Number of subjects: 75
Study 9104574 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (58% energy, n = 57)
Number of subjects: 110
Study 9104574 — intervention group
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet (35% energy, n = 53)
Number of subjects: 110
Study 1443811 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 90
Study 1443811 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 1 g
Number of subjects: 90
Study 1443811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 3888730 — intervention group
Group type: EXPERIMENTAL
Intervention: Limbitrol (25 mg amitriptyline and 10 mg chlordiazepoxide)
Number of subjects: 434
Study 3888730 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline 25 mg
Number of subjects: 434
Study 30679302 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide plus basal insulin
Number of subjects: 150
Study 30679302 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide alone
Number of subjects: 150
Study 30679302 — intervention group
Group type: COMPARATOR
Intervention: Basal-bolus insulin regimen
Number of subjects: 150
Study 30679302 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide and exenatide plus basal
Number of subjects: 150
Study 30679302 — intervention group
Group type: COMPARATOR
Intervention: Basal-bolus group
Number of subjects: 150
Study 30679302 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide plus basal, exenatide, and basal-bolus groups
Number of subjects: 150
Study 29760860 — intervention group
Group type: EXPERIMENTAL
Intervention: Refresher training in scripted communication
Number of subjects: 474
Study 29760860 — intervention group
Group type: COMPARATOR
Intervention: No instruction or other intervention related to communication (Control)
Number of subjects: 474
Study 27617661 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (400 mg twice a day)
Number of subjects: 265
Study 27617661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study 27617661 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (400 mg twice a day) in patients with BRCAm
Number of subjects: 265
Study 27617661 — intervention group
Group type: COMPARATOR
Intervention: Placebo in patients with BRCAm
Number of subjects: 265
Study 27617661 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (400 mg twice a day) in patients with BRCA wild-type
Number of subjects: 265
Study 27617661 — intervention group
Group type: COMPARATOR
Intervention: Placebo in patients with BRCA wild-type
Number of subjects: 265
Study 24890483 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit-based messages
Number of subjects: 71
Study 24890483 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-group messages
Number of subjects: 71
Study 24890483 — intervention group
Group type: EXPERIMENTAL
Intervention: General healthy eating messages
Number of subjects: 71
Study 24890483 — intervention group
Group type: COMPARATOR
Intervention: Delivery method (e-mail vs sms)
Number of subjects: 71
Study 21959915 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 287
Study 21959915 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural group therapy
Number of subjects: 287
Study 21959915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study 20151799 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus simvastatin (SMV) 1.2 mg
Number of subjects: 60
Study 20151799 — intervention group
Group type: COMPARATOR
Intervention: SRP plus placebo
Number of subjects: 60
Study 18849894 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation oral antipsychotics (short-term, 5 days)
Number of subjects: 36
Study 16009795 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy (atorvastatin 80 mg/d)
Number of subjects: 615
Study 16009795 — intervention group
Group type: COMPARATOR
Intervention: Moderate therapy (pravastatin 40 mg/d)
Number of subjects: 615
Study 16009795 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 615
Study 11850333 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Information Leaflet (FIL)
Number of subjects: 175
Study 11850333 — intervention group
Group type: COMPARATOR
Intervention: Standard information without FIL
Number of subjects: 175
Study 9920080 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized 17beta‐estradiol [0.5 mg/day Estrace (E2)]
Number of subjects: 31
Study 9920080 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg/day elemental calcium, given as carbonate plus vitamin D (800 IU/day; Ca+D)
Number of subjects: 31
Study 9920080 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Ca+D and E2)
Number of subjects: 31
Study 9920080 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 31
Study 7559274 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient intervention program with asthma specialist (allergist/immunologist)
Number of subjects: 84
Study 7559274 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention group followed by general internist or pediatrician
Number of subjects: 84
Study 2345485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine (16 mg)
Number of subjects: 14
Study 2345485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30553760 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical model (1)
Number of subjects: 544
Study 30553760 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalized FDG uptake from Cox-ROI only (2)
Number of subjects: 544
Study 30553760 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalized FDG uptake from ANCOVA-ROI only (3)
Number of subjects: 544
Study 30553760 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical variables plus FDG uptake in ANCOVA-ROI (4)
Number of subjects: 544
Study 30553760 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical variables plus FDG uptake from Cox-ROI (5)
Number of subjects: 544
Study 27416915 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF)/ledipasvir for 8 weeks
Number of subjects: 18
Study 27416915 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF)/ledipasvir for 12 weeks
Number of subjects: 18
Study 27416915 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF)/ledipasvir/ribavirin for 12 weeks
Number of subjects: 18
Study 27416915 — intervention group
Group type: EXPERIMENTAL
Intervention: Paritaprevir/r, ombitasvir, dasabuvir for 12 weeks
Number of subjects: 18
Study 27416915 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF)/ledipasvir for 12 weeks in treatment experienced patients without cirrhosis
Number of subjects: 18
Study 27416915 — intervention group
Group type: EXPERIMENTAL
Intervention: Paritaprevir/r, ombitasvir, dasabuvir ± ribavirin for 12 weeks in treatment experienced patients without cirrhosis
Number of subjects: 18
Study 27416915 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF)/ledipasvir for 24 weeks in re-treated cirrhotic individuals
Number of subjects: 18
Study 27416915 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF)/daclatasvir for 24 weeks in re-treated cirrhotic individuals
Number of subjects: 18
Study 27416915 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF)/simeprevir/1200 mg/d ribavirin for 12 weeks in re-treated cirrhotic individuals
Number of subjects: 18
Study 25531033 — intervention group
Group type: EXPERIMENTAL
Intervention: Angelica keiskei Koidzumi (AKE) supplementation
Number of subjects: 82
Study 25531033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 23530022 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 12944
Study 21272454 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon a‐1b (50mug I. M., qod)
Number of subjects: 111
Study 21272454 — intervention group
Group type: COMPARATOR
Intervention: Interferon a‐1b combined with lamivudine (100 mg, P.O., q.d. for 6-12 months or longer)
Number of subjects: 111
Study 21272454 — intervention group
Group type: COMPARATOR
Intervention: Interferon a‐1b combined with lamivudine
Number of subjects: 111
Study 19637345 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based walking intervention (exercise)
Number of subjects: 126
Study 19637345 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 126
Study 17605253 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial dermis and recombinant bFGF2 spray, applied twice a day after immersion bath, dressing changed every other day or every 2 days
Number of subjects: 56
Study 17605253 — intervention group
Group type: COMPARATOR
Intervention: Monolayer gauze wetted with povidone iodine
Number of subjects: 56
Study 15127239 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of serum tumour markers (CA 15.3, CEA, TPA, TPS, Cyfra 21.1) for monitoring therapeutic response.
Number of subjects: 0
Study 15127239 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of serum markers for diagnosis of recurrent disease.
Number of subjects: 0
Study 15127239 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective randomised studies on serum markers for earlier therapeutic interventions.
Number of subjects: 0
Study 11483170 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive task involving sequential learning, explicit processing, and working memory
Number of subjects: 0
Study 9783295 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% nitrous oxide (N2O)
Number of subjects: 20
Study 9783295 — intervention group
Group type: COMPARATOR
Intervention: 100% oxygen (O2)
Number of subjects: 20
Study 7522906 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (2 x 10(6) KI units intravenous bolus and 0.5 x 10(6) KI units h‐1 plus 2 x 10(6) KI units into pump prime)
Number of subjects: 100
Study 7522906 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin added to pump prime (2 x 10(6) KI units)
Number of subjects: 100
Study 7522906 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient group (aprotinin 10(6) KI units intravenous bolus plus 10(6) KI units added to pump prime)
Number of subjects: 100
Study 7522906 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.9 per cent saline placebo)
Number of subjects: 100
Study 2839632 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide (EVAC)
Number of subjects: 136
Study 2839632 — intervention group
Group type: COMPARATOR
Intervention: VAC (vincristine, doxorubicin, cyclophosphamide)
Number of subjects: 136
Study 31672793 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended dialysis hours
Number of subjects: 200
Study 29745114 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatin tannate (GT)
Number of subjects: 0
Study 29745114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25698173 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichuris suis ova therapy, 2500 ova orally every second week for 12 weeks
Number of subjects: 10
Study 25698173 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 10
Study 22963881 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 99
Study 22963881 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modification
Number of subjects: 99
Study 21572019 — intervention group
Group type: COMPARATOR
Intervention: External counterpulsation (ECP)
Number of subjects: 20
Study 21572019 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle exercise
Number of subjects: 20
Study 17922185 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (exemestane and letrozole)
Number of subjects: 100
Study 16820790 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (750 mg/m2, 13 pulses in 2 years) combined with oral prednisone (CY)
Number of subjects: 87
Study 16820790 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (2 mg/kg/day in 2 years) combined with intravenous pulses of methylprednisolone (3 x 3 pulses of 1000 mg) and oral prednisone (AZA)
Number of subjects: 87
Study 16820790 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 87
Study 12637117 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine TDS 35.0 microg/h
Number of subjects: 157
Study 12637117 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine TDS 52.5 microg/h
Number of subjects: 157
Study 12637117 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine TDS 70.0 microg/h
Number of subjects: 157
Study 12637117 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine TDS
Number of subjects: 157
Study 12637117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 10710845 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailings-only intervention (8 relapse-prevention booklets mailed over 1 year)
Number of subjects: 584
Study 10710845 — intervention group
Group type: COMPARATOR
Intervention: Control condition (non-mailing conditions)
Number of subjects: 584
Study 10710845 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined conditions (both interventions)
Number of subjects: 584
Study 10710845 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot-line-only intervention (12-month access to a telephone hot line)
Number of subjects: 584
Study 9181182 — intervention group
Group type: EXPERIMENTAL
Intervention: Norplant
Number of subjects: 180
Study 9181182 — intervention group
Group type: COMPARATOR
Intervention: IUD
Number of subjects: 180
Study 1492307 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 110
Study 1492307 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splint therapy
Number of subjects: 110
Study 1492307 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 110
Study 1492307 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment modes
Number of subjects: 110
Study 1492307 — intervention group
Group type: EXPERIMENTAL
Intervention: Algometer
Number of subjects: 110
Study 2993690 — intervention group
Group type: EXPERIMENTAL
Intervention: SBT/CPZ (0.5 g SBT + 0.5 g CPZ, 2 times/day)
Number of subjects: 137
Study 2993690 — intervention group
Group type: COMPARATOR
Intervention: CZX (1.0 g, 2 times/day)
Number of subjects: 137
Study 2993690 — intervention group
Group type: EXPERIMENTAL
Intervention: SBT/CPZ
Number of subjects: 137
Study 2993690 — intervention group
Group type: COMPARATOR
Intervention: CZX
Number of subjects: 137
Study 31729647 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy group (target serum UA level ≥ 4.0 mg/dL, < 5.0 mg/dL)
Number of subjects: 370
Study 31729647 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy group (serum UA level ≥ 6.0 mg/dL, < 7.0 mg/dL)
Number of subjects: 370
Study 31729647 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy group
Number of subjects: 370
Study 31729647 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy group
Number of subjects: 370
Study 29453772 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrasulcular incision
Number of subjects: 60
Study 29453772 — intervention group
Group type: COMPARATOR
Intervention: Paramarginal incision
Number of subjects: 60
Study 28065445 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (1mg once daily for 1 month plus optimal medical treatment)
Number of subjects: 44
Study 28065445 — intervention group
Group type: COMPARATOR
Intervention: Control (optimal medical treatment only)
Number of subjects: 44
Study 26278118 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 12
Study 26278118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 24140959 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency Doubling Technology (FDT) perimetry
Number of subjects: 20
Study 24140959 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects (control group)
Number of subjects: 20
Study 21493743 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (prednisolone, azathioprine, heparin‐warfarin, and dipyridamole)
Number of subjects: 78
Study 21493743 — intervention group
Group type: COMPARATOR
Intervention: Control therapy (heparin‐warfarin and dipyridamole)
Number of subjects: 78
Study 21493743 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 78
Study 21493743 — intervention group
Group type: COMPARATOR
Intervention: Control therapy
Number of subjects: 78
Study 19110789 — intervention group
Group type: EXPERIMENTAL
Intervention: TITANOX-coated stent
Number of subjects: 425
Study 19110789 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 425
Study 17133785 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone combined with metformin (1500 mg/day increasing to 3000 mg/day)
Number of subjects: 103
Study 17133785 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone combined with metformin (1500 mg/day increasing to 3000 mg/day)
Number of subjects: 103
Study 15612454 — intervention group
Group type: EXPERIMENTAL
Intervention: Poloxamer 188 (n = 4)
Number of subjects: 9
Study 15612454 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 5)
Number of subjects: 9
Study 11478141 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant hormonal therapy
Number of subjects: 0
Study 9252771 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid + PVP-I treatment
Number of subjects: 15
Study 9252771 — intervention group
Group type: COMPARATOR
Intervention: Hydrocolloid treatment
Number of subjects: 15
Study 8389339 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat meal (30 g margarine; 1327 kJ (317 kcal))
Number of subjects: 15
Study 8389339 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat meal (301 kJ (72 kcal))
Number of subjects: 15
Study 3040455 — intervention group
Group type: COMPARATOR
Intervention: ACTH 4-10 (0 mg)
Number of subjects: 12
Study 3040455 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH 4-10 (0.1 mg)
Number of subjects: 12
Study 3040455 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH 4-10 (1.0 mg)
Number of subjects: 12
Study 3040455 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH 4-10 (10 mg)
Number of subjects: 12
Study 30003102 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) treatment for 36 sessions
Number of subjects: 242
Study 30003102 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram treatment
Number of subjects: 242
Study 26852398 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB treatment (n=26)
Number of subjects: 73
Study 26852398 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol injection (n=20)
Number of subjects: 73
Study 26852398 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=27)
Number of subjects: 73
Study 23837834 — intervention group
Group type: EXPERIMENTAL
Intervention: Applanation Resonance Tonometry (ART)
Number of subjects: 153
Study 23837834 — intervention group
Group type: COMPARATOR
Intervention: Goldmann Applanation Tonometry (GAT)
Number of subjects: 153
Study 23837834 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ART and GAT
Number of subjects: 153
Study 23837834 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-examiner variability
Number of subjects: 153
Study 23837834 — intervention group
Group type: EXPERIMENTAL
Intervention: Influence of Central Corneal Thickness (CCT)
Number of subjects: 153
Study 23131064 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic treatment plus usual care
Number of subjects: 165
Study 23131064 — intervention group
Group type: COMPARATOR
Intervention: Supportive listening plus usual care
Number of subjects: 165
Study 23131064 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 165
Study 19774349 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (50 mg daily)
Number of subjects: 38
Study 19774349 — intervention group
Group type: COMPARATOR
Intervention: No zinc supplementation
Number of subjects: 38
Study 19774349 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 38
Study 18337049 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone
Number of subjects: 28
Study 18337049 — intervention group
Group type: EXPERIMENTAL
Intervention: Videophone
Number of subjects: 28
Study 18337049 — intervention group
Group type: COMPARATOR
Intervention: Nurse perceptions
Number of subjects: 28
Study 15562251 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO+PRO+Leu
Number of subjects: 8
Study 15562251 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO+PRO
Number of subjects: 8
Study 15562251 — intervention group
Group type: COMPARATOR
Intervention: CHO
Number of subjects: 8